• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines.

作者信息

Lacouture M E, Sibaud V, Gerber P A, van den Hurk C, Fernández-Peñas P, Santini D, Jahn F, Jordan K

机构信息

Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.

Department of Oncodermatology, Claudius Regaud Institute, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France.

出版信息

Ann Oncol. 2021 Feb;32(2):157-170. doi: 10.1016/j.annonc.2020.11.005. Epub 2020 Nov 25.

DOI:10.1016/j.annonc.2020.11.005
PMID:33248228
Abstract
摘要

相似文献

1
Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines.抗癌药物相关皮肤毒性的预防与管理：ESMO临床实践指南
Ann Oncol. 2021 Feb;32(2):157-170. doi: 10.1016/j.annonc.2020.11.005. Epub 2020 Nov 25.
2
Meta-analysis of dermatological toxicities associated with sorafenib.索拉非尼相关皮肤毒性的荟萃分析。
Clin Exp Dermatol. 2011 Jun;36(4):344-50. doi: 10.1111/j.1365-2230.2011.04060.x. Epub 2011 Apr 20.
3
How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors?MESTT 与 CTCAE 量表在评估与口服酪氨酸激酶抑制剂相关的皮肤毒性方面的相关性如何？
Support Care Cancer. 2011 Oct;19(10):1667-74. doi: 10.1007/s00520-010-0999-2. Epub 2010 Sep 5.
4
Skin Manifestations of Targeted Antineoplastic Therapy.靶向抗肿瘤治疗的皮肤表现
Curr Probl Dermatol. 2018;53:93-104. doi: 10.1159/000479198. Epub 2017 Nov 7.
5
Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.索拉非尼治疗实体瘤患者的黏膜皮肤毒性风险：一项更新的系统评价和荟萃分析。
Expert Rev Anticancer Ther. 2014 Jun;14(6):751-60. doi: 10.1586/14737140.2014.894465. Epub 2014 Mar 26.
6
Non-rash skin toxicities associated with novel targeted therapies.与新型靶向疗法相关的非皮疹性皮肤毒性
Clin Lung Cancer. 2006 Dec;8 Suppl 1:S36-42. doi: 10.3816/clc.2006.s.012.
7
Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.EGFR 抑制剂相关性皮肤毒性的预防和治疗临床实践指南。
Support Care Cancer. 2011 Aug;19(8):1079-95. doi: 10.1007/s00520-011-1197-6. Epub 2011 Jun 1.
8
Risk of selected dermatological toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis.接受MEK抑制剂治疗的癌症患者发生特定皮肤毒性的风险：一项比较性系统评价和荟萃分析。
Future Oncol. 2015;11(24):3307-19. doi: 10.2217/fon.15.265. Epub 2015 Nov 12.
9
Acneiform eruption induced by molecularly targeted agents in antineoplastic therapy: A review.抗肿瘤治疗中分子靶向药物引起的痤疮样疹：综述。
J Cosmet Dermatol. 2023 Aug;22(8):2150-2157. doi: 10.1111/jocd.15704. Epub 2023 Mar 16.
10
The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: a systematic review and meta-analysis.黑色素瘤患者中联合BRAF和MEK抑制与单独BRAF抑制相比的皮肤毒性风险：一项系统评价和荟萃分析。
Cutan Ocul Toxicol. 2019 Jun;38(2):105-111. doi: 10.1080/15569527.2018.1553180. Epub 2019 Jan 28.

引用本文的文献

1
Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial.甲钴胺对HER2阴性早期乳腺癌患者卡培他滨所致手足综合征的影响：多中心、双盲、随机、安慰剂对照3期试验
BMJ. 2025 Sep 11;390:e084290. doi: 10.1136/bmj-2025-084290.
2
Epidermal growth factor receptor inhibitor-related skin toxicities: a review of management and possible preventive and therapeutic approaches for Asian patients by the Japanese Pharmacist-led Oncodermatology Study Team.表皮生长因子受体抑制剂相关皮肤毒性：日本药师主导的肿瘤皮肤病学研究团队对亚洲患者管理及可能的预防和治疗方法的综述
Int J Clin Oncol. 2025 Sep 1. doi: 10.1007/s10147-025-02868-1.
3
Skin Reactions and Other Underappreciated Dermatologic Side Effects of Cancer Therapies.癌症治疗的皮肤反应及其他未得到充分重视的皮肤科副作用
Curr Treat Options Oncol. 2025 Aug 14. doi: 10.1007/s11864-025-01333-5.
4
Scalp cooling for the prevention of chemotherapy-induced alopecia in women with early breast cancer.头皮冷却预防早期乳腺癌女性化疗所致脱发
Cochrane Database Syst Rev. 2025 Aug 1;8(8):CD016196. doi: 10.1002/14651858.CD016196.
5
Mitigation and management of adverse events associated with amivantamab therapy.与氨甲环酸治疗相关的不良事件的缓解与管理。 （注：你原文中“amivantamab”有误，正确的是“amivantamab-vmjw”，中文名为“氨甲环酸单抗”，这里按照你提供的错误名称翻译了，实际应用中请按正确名称处理。） 如果按照正确药物名称准确翻译为：与氨甲环酸单抗治疗相关的不良事件的缓解与管理。
Oncologist. 2025 Jul 4;30(7). doi: 10.1093/oncolo/oyaf194.
6
Dermatologic Adverse Event Mitigation and Management Strategies with Amivantamab + Lazertinib Therapy for Advanced Non-Small Cell Lung Cancer: A Vodcast.阿美替尼单抗+拉泽替尼治疗晚期非小细胞肺癌的皮肤不良事件缓解与管理策略：视频播客
Target Oncol. 2025 Jun 21. doi: 10.1007/s11523-025-01163-3.
7
Safety and Adverse Event Management of VEGFR-TKIs in Patients With Metastatic Renal Cell Carcinoma.转移性肾细胞癌患者中VEGFR-TKIs的安全性及不良事件管理
Clin J Oncol Nurs. 2025 May 19;29(3):219-229. doi: 10.1188/25.CJON.219-229.
8
A randomized, double-blind, placebo-controlled phase III study evaluating the preventive effect of diclofenac cream on capecitabine-related hand-foot syndrome: study protocol of J-SUPPORT2401/JORTC-SUP06 (J-DIRECT).一项评估双氯芬酸乳膏对卡培他滨相关性手足综合征预防作用的随机、双盲、安慰剂对照III期研究：J-SUPPORT2401/JORTC-SUP06（J-DIRECT）研究方案
Int J Clin Oncol. 2025 May 14. doi: 10.1007/s10147-025-02789-z.
9
Navigating antibody‒drug conjugates (ADCs): from metastatic to early breast cancer treatment strategies.探索抗体药物偶联物（ADCs）：从转移性乳腺癌到早期乳腺癌的治疗策略
Invest New Drugs. 2025 Apr 30. doi: 10.1007/s10637-025-01525-8.
10
Best evidence summary for preventing and preventing epidermal growth factor receptor inhibitors induced paronychia in cancer patients.预防癌症患者表皮生长因子受体抑制剂所致甲沟炎的最佳证据总结
Front Oncol. 2025 Apr 14;15:1555114. doi: 10.3389/fonc.2025.1555114. eCollection 2025.